Sharps Technology (STSS) Life Sciences Virtual Investor Forum summary

Company overview and recent milestones

• Specializes in smart safety and prefillable syringe products, founded in 2017, IPO in 2022.

• Acquired a fully operational, vertically integrated syringe facility in Hungary post-IPO.

• Products have FDA, CE, and WHO approvals, targeting specialized medical device markets.

• Achieved first revenues and commercialized three products, including SoloGard, SecureGard, and an autoinjector syringe.

• Raised $20 million to expand European facility and support a $50 million U.S. sales agreement.

Manufacturing and expansion plans

• European facility is debt-free, 40,000-45,000 sq ft, and expandable for future agreements.

• $5 million invested in new equipment and cleanroom upgrades to support large U.S. contract.

• Negotiating to acquire a 100,000 sq ft facility in South Carolina for prefilled syringe production.

• Plans to launch Barrigex prefilled syringe platform, with molds and samples already produced.

• Facility in Hungary supports current agreements; U.S. expansion aims to serve both U.S. and European markets.

Product and market insights

• Smart safety syringes feature ultra-low waste and reuse prevention technologies.

• Prefilled syringes, especially those using copolymer materials, offer higher margins and are a fast-growing market.

• Prefilled syringes enable precise dosing and are favored for biologics, branded, and generic drugs.

• Prefilled syringes sell for $1.50-$6 each, with margins of 50%-80%.

• Market growth driven by pharmaceutical investment in filling technology and drug shortages.